Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2025 Feb;77(2):257-265.
doi: 10.1002/acr.25196. Epub 2023 Sep 5.

Tricuspid Annular Plane Systolic Excursion/Systolic Pulmonary Artery Pressure Ratio and Cardiorenal Syndrome Type 2 in the Systemic Sclerosis EUSTAR Cohort

Amalia Colalillo  1 , Chiara Pellicano  1 , Lidia P Ananyeva  2 , Eric Hachulla  3 , Giovanna Cuomo  4 , Andrea-Hermina Györfi  5 , László Czirják  6 , Jeska de Vries-Bouwstra  7 , Luc Mouthon  8 , Hadi Poormoghim  9 , Francesco Del Galdo  10 , Nicolas Hunzelmann  11 , Julia Spierings  12 , Masataka Kuwana  13 , Edoardo Rosato  1 ; and the EUSTAR Collaborators
Collaborators, Affiliations

Tricuspid Annular Plane Systolic Excursion/Systolic Pulmonary Artery Pressure Ratio and Cardiorenal Syndrome Type 2 in the Systemic Sclerosis EUSTAR Cohort

Amalia Colalillo et al. Arthritis Care Res (Hoboken). 2025 Feb.

Abstract

Objective: The aim of the study was to evaluate the association between the tricuspid annular plane systolic excursion (TAPSE)/systolic pulmonary artery pressure (sPAP) ratio and estimated glomerular filtration rate (eGFR) and their association with mortality in the European Scleroderma Trials and Research (EUSTAR) cohort.

Methods: Patients with systemic sclerosis (SSc) from the EUSTAR database with TAPSE, sPAP, and parameters required to calculate eGFR were included. Logistic regression and Cox regression analysis were performed to evaluate TAPSE/sPAP as a risk factor for chronic kidney disease (CKD) and overall survival.

Results: A total of 2,370 patients with SSc were included; 284 (12%) patients had CKD stage 3a-5. TAPSE/sPAP (odds ratio [OR] 0.479; 95% CI 0.310-0.743; P < 0.001), arterial hypertension (OR 3.118; 95% CI 2.173-4.475; P < 0.001), diastolic dysfunction (OR 1.670; 95% CI 1.148-2.428; P < 0.01), and N-terminal pro-B-type natriuretic peptide (OR 1.165; 95% CI 1.041-1.304; P < 0.01) were associated with CKD stage 3a-5. TAPSE/sPAP ≤0.32 mm/mm Hg (hazard ratio [HR] 3.589; 95% CI 2.236-5.761; P < 0.001), eGFR <60 mL/min per 1.73 m2 (HR 2.818; 95% CI 1.777-4.468; P < 0.001), and age (HR 1.782; 95% CI 1.348-2.356; P < 0.001) were the most significant predictive factors for all-cause mortality. A total of 276 patients with SSc had pulmonary hypertension (PH) confirmed by right-sided heart catheterization, with 69 (25%) having CKD stage 3a-5. No difference was found in eGFR between patients with PH with reduced or normal cardiac index.

Conclusion: Reduced TAPSE/sPAP ratio is independently associated with CKD. TAPSE/sPAP ratio ≤0.32 mm/mm Hg and eGFR <60 mL/min per 1.73 m2 are prognostic factors for all-cause mortality. In patients with SSc with PH, eGFR is independent by reduced cardiac output.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Tricuspid annular plane systolic excursion (TAPSE)/systolic pulmonary artery pressure (sPAP) ratio and estimated glomerular filtration rate (eGFR) in systemic sclerosis patients. (A) Correlation between TAPSE/sPAP ratio and eGFR; (B) eGFR in patients with and without TAPSE/sPAP ratio <0.55 mm/mm Hg.
Figure 2
Figure 2
Overall survival in 2,271 patients with systemic sclerosis (SSc). (A) Overall survival in patients with SSc with tricuspid annular plane systolic excursion (TAPSE)/systolic pulmonary artery pressure (sPAP) ratio ≤0.32 mm/mm Hg (dotted line) and TAPSE/sPAP ratio >0.32 mm/mm Hg (continuous line); (B) overall survival in patients with SSc with estimated glomerular filtration rate (eGFR) <60 mL/min per 1.73 m2 (dotted line) and eGFR ≥60 mL/min per 1.73 m2 (continuous line).
See this image and copyright information in PMC

References

    1. Elhai M, Meune C, Boubaya M, et al. Mapping and predicting mortality from systemic sclerosis. Ann Rheum Dis 2017;76:1897–905. - PubMed
    1. Lin CY, Chen HA, Chang TW, et al. Association of systemic sclerosis with incident clinically evident heart failure. Arthritis Care Res (Hoboken) 2023;75:1452–61. - PubMed
    1. Ruaro B, Confalonieri M, Salton F, et al. The relationship between pulmonary damage and peripheral vascular manifestations in systemic sclerosis patients [review]. Pharmaceuticals (Basel) 2021;14:403. - PMC - PubMed
    1. Vonk Noordegraaf A, Westerhof BE, Westerhof N. The relationship between the right ventricle and its load in pulmonary hypertension [review]. J Am Coll Cardiol 2017;69:236–43. - PubMed
    1. Benza RL, Miller DP, Gomberg‐Maitland M, et al. Predicting survival in pulmonary arterial hypertension: insights from the Registry to Evaluate Early and Long‐Term Pulmonary Arterial Hypertension Disease Management (REVEAL). Circulation 2010;122:164–72. - PubMed

MeSH terms